Literature DB >> 21821527

The role of comorbidities in cardioprotection.

Michael N Sack1, Elizabeth Murphy.   

Abstract

Cardioprotective strategies such as pre- and postconditioning result in a robust reduction in infarct size in young, healthy male animals. However, there are data suggesting that the protection is diminished in animals with comorbidities such as hypertension, hypercholesterolemia, and diabetes. It is important to understand at a mechanistic level the reasons for these differences. The effects of sex and diseases need to be considered in design of cardioprotective interventions in animal studies and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821527      PMCID: PMC3398382          DOI: 10.1177/1074248411408313

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  53 in total

1.  Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus.

Authors:  Jian Xu; Yong Wu; Ping Song; Miao Zhang; Shuangxi Wang; Ming-Hui Zou
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

Review 2.  Type 2 diabetes, mitochondrial biology and the heart.

Authors:  Michael N Sack
Journal:  J Mol Cell Cardiol       Date:  2009-02-13       Impact factor: 5.000

Review 3.  Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease.

Authors:  An L Moens; David A Kass
Journal:  J Cardiovasc Pharmacol       Date:  2007-09       Impact factor: 3.105

4.  Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults?

Authors:  Gary L Pierce; Thomas J Larocca
Journal:  J Physiol       Date:  2008-04-03       Impact factor: 5.182

Review 5.  The impairment of preconditioning-mediated cardioprotection in pathological conditions.

Authors:  Pitchai Balakumar; Harsimran Singh; Manjeet Singh; Madhu B Anand-Srivastava
Journal:  Pharmacol Res       Date:  2009-03-13       Impact factor: 7.658

6.  Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus.

Authors:  Naoto Sasaki; Tomoya Yamashita; Tomofumi Takaya; Masakazu Shinohara; Rio Shiraki; Masafumi Takeda; Noriaki Emoto; Akiko Fukatsu; Toshio Hayashi; Kazuhisa Ikemoto; Takahide Nomura; Mitsuhiro Yokoyama; Ken-Ichi Hirata; Seinosuke Kawashima
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-10       Impact factor: 8.311

7.  Why did the NHE inhibitor clinical trials fail?

Authors:  Elizabeth Murphy; David G Allen
Journal:  J Mol Cell Cardiol       Date:  2008-11-05       Impact factor: 5.000

8.  Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4.

Authors:  Cristian Dumitrescu; Roberto Biondi; Yong Xia; Arturo J Cardounel; Lawrence J Druhan; Giuseppe Ambrosio; Jay L Zweier
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-11       Impact factor: 11.205

9.  L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  M Settergren; F Böhm; R E Malmström; K M Channon; J Pernow
Journal:  Atherosclerosis       Date:  2008-09-04       Impact factor: 5.162

10.  Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C epsilon phosphorylation.

Authors:  Ken Shinmura; Maiko Nagai; Kayoko Tamaki; Roberto Bolli
Journal:  Cardiovasc Res       Date:  2008-04-04       Impact factor: 10.787

View more
  12 in total

1.  The clinical impact of sex differences on ischemic postconditioning during primary percutaneous coronary intervention: a POST (the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction) substudy.

Authors:  Eun-Seok Shin; Ju-Hyun Chung; Joo-Yong Hahn; Young Bin Song; Eun Kyoung Kim; Cheol Woong Yu; Jang-Whan Bae; Woo-Young Chung; Seung-Hyuk Choi; Jin-Ho Choi; Jang-Ho Bae; Kyung Joo An; Jong-Seon Park; Ju Hyeon Oh; Sang-Wook Kim; Jin-Yong Hwang; Jae Kean Ryu; Scot Garg; Do-Sun Lim; Hyeon-Cheol Gwon; Hun Sik Park
Journal:  Heart Vessels       Date:  2018-12-05       Impact factor: 2.037

Review 2.  Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.

Authors:  Massimo Bonora; Mariusz R Wieckowski; David A Sinclair; Guido Kroemer; Paolo Pinton; Lorenzo Galluzzi
Journal:  Nat Rev Cardiol       Date:  2019-01       Impact factor: 32.419

Review 3.  Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.

Authors:  Tetsuji Miura; Tatsuya Sato; Toshiyuki Yano; Akira Takaguri; Takayuki Miki; Noritsugu Tohse; Keitaro Nishizawa
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-12       Impact factor: 3.727

4.  Should the STAIR criteria be modified for preconditioning studies?

Authors:  Michael M Wang; Guohua Xi; Richard F Keep
Journal:  Transl Stroke Res       Date:  2013-02       Impact factor: 6.829

5.  Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats.

Authors:  Wenna Li; Nan Wu; Wenqi Shu; Dalin Jia; Pengyu Jia
Journal:  Exp Ther Med       Date:  2015-10-01       Impact factor: 2.447

6.  Hypercholesterolemic myocardium is vulnerable to ischemia-reperfusion injury and refractory to sevoflurane-induced protection.

Authors:  Yong Xu; Lei-Lei Ma; Chen Zhou; Fei-Jiang Zhang; Fei-Juan Kong; Wen-Na Wang; Ling-Bo Qian; Can-Can Wang; Xian-Bao Liu; Min Yan; Jian-An Wang
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

7.  SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart.

Authors:  Ven G Lim; Robert M Bell; Sapna Arjun; Maria Kolatsi-Joannou; David A Long; Derek M Yellon
Journal:  JACC Basic Transl Sci       Date:  2019-01-30

Review 8.  Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart.

Authors:  Cinzia Perrino; Péter Ferdinandy; Hans E Bøtker; Bianca J J M Brundel; Peter Collins; Sean M Davidson; Hester M den Ruijter; Felix B Engel; Eva Gerdts; Henrique Girao; Mariann Gyöngyösi; Derek J Hausenloy; Sandrine Lecour; Rosalinda Madonna; Michael Marber; Elizabeth Murphy; Maurizio Pesce; Vera Regitz-Zagrosek; Joost P G Sluijter; Sabine Steffens; Can Gollmann-Tepeköylü; Linda W Van Laake; Sophie Van Linthout; Rainer Schulz; Kirsti Ytrehus
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

9.  Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes.

Authors:  Lydia Lacerda; Lionel H Opie; Sandrine Lecour
Journal:  Exp Diabetes Res       Date:  2012-10-17

10.  Effects of tetracycline on myocardial infarct size in obese rats with chemically-induced colitis.

Authors:  Yury Yu Borshchev; Sarkis M Minasian; Inessa Yu Burovenko; Victor Yu Borshchev; Egor S Protsak; Natalia Yu Semenova; Olga V Borshcheva; Michael M Galagudza
Journal:  PLoS One       Date:  2019-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.